Brooks Laboratories Limited
NSE: BROOKS BSE: BROOKS
NSE
131.76
-2.49 (-1.85%)
Prev Close
134.25
Open Price
134.25
Volume
38,578
Today Low / High
130.3 / 135
52 WK Low / High
95.55 / 198.86
Range
125 - 138
BSE
131.55
-3.50 (-2.59%)
Prev Close
135.05
Open Price
135
Volume
4,732
Today Low / High
131.35 / 135
52 WK Low / High
97.8 / 202.8
Range
125 - 138
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 131.76 (target range: 125 - 138), reflecting a change of -2.49 (-1.85475%). On the BSE, it is listed at 131.55 (target range: 125 - 138), showing a change of -3.5 (-2.59163%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
01 Oct
134.25
-1.85%
30 Sep
135.01
-0.56%
29 Sep
142.27
-5.00%
26 Sep
142.00
-4.58%
25 Sep
146.75
-3.52%
24 Sep
146.95
-1.04%
23 Sep
149.00
-2.07%
22 Sep
145.00
1.43%
19 Sep
156.99
-4.85%
18 Sep
154.99
-3.27%
17 Sep
157.00
-1.45%
16 Sep
160.00
-2.17%
15 Sep
161.40
-2.45%
12 Sep
153.00
3.95%
11 Sep
152.88
-0.20%
10 Sep
148.00
2.25%
09 Sep
145.00
0.56%
08 Sep
152.99
-3.44%
05 Sep
152.80
-1.15%
04 Sep
145.53
0.00%
Brooks Laboratories Limited Graph
Brooks Laboratories Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Brooks Laboratories Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 131.76, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 131.55 | 132.87 | 119.58 - 146.15 |
| 134.18 | 107.34 - 161.02 | ||
| 135.50 | 94.85 - 176.15 | ||
| Bearish Scenario | 131.55 | 130.23 | 117.21 - 143.26 |
| 128.92 | 103.14 - 154.70 | ||
| 127.60 | 89.32 - 165.88 |
Overview of Brooks Laboratories Limited
ISIN
INE650L01011
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
27,014
Market Cap
3,881,286,996
Last Dividend
0
Official Website
IPO Date
2011-09-05
DCF Diff
269.87
DCF
-135
Financial Ratios Every Investor Needs
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 82.56 Cr | 68.63 Cr | 13.92 Cr | 0.1686 | 0.00 Cr | 0.00 Cr | 3.34 Cr | -9.97 Cr | -3.29 | 5.82 Cr | -0.1207 |
| 2024-03-31 | 79.49 Cr | 72.92 Cr | 22.51 Cr | 0.2832 | 0.00 Cr | 4.37 Cr | 1.20 Cr | -19.59 Cr | -7.65 | 4.17 Cr | -0.2465 |
| 2023-03-31 | 62.48 Cr | 50.60 Cr | 12.60 Cr | 0.2017 | 0.00 Cr | 10.09 Cr | -6.90 Cr | -20.90 Cr | -8.38 | -29.17 Cr | -0.3345 |
| 2022-03-31 | 91.18 Cr | 75.80 Cr | -7.91 Cr | -0.0868 | 0.00 Cr | 8.84 Cr | 7.74 Cr | -19.31 Cr | -7.74 | -13.45 Cr | -0.2118 |
| 2021-03-31 | 77.07 Cr | 55.24 Cr | 21.83 Cr | 0.2832 | 0.00 Cr | 6.55 Cr | -10.84 Cr | -19.38 Cr | -7.77 | 1.25 Cr | -0.2514 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1.25 Cr | 123.69 Cr | 25.59 Cr | 98.1043 Cr | 7.58 Cr | 6.33 Cr | 9.20 Cr | 13.97 Cr | 0.00 Cr | 0.00 Cr | 73.69 Cr | 22.8441 Cr |
| 2024-03-31 | 0.13 Cr | 90.45 Cr | 24.86 Cr | 65.5853 Cr | 5.64 Cr | 5.52 Cr | 9.61 Cr | 13.60 Cr | 0.26 Cr | 0.00 Cr | 42.91 Cr | 23.0476 Cr |
| 2023-03-31 | 0.02 Cr | 109.60 Cr | 35.64 Cr | 73.9532 Cr | 6.51 Cr | 6.49 Cr | 11.30 Cr | 14.81 Cr | 1.14 Cr | 0.00 Cr | 64.19 Cr | 33.0213 Cr |
| 2022-03-31 | 2.61 Cr | 195.91 Cr | 61.59 Cr | 87.4901 Cr | 25.26 Cr | 22.65 Cr | 27.52 Cr | 124.49 Cr | 3.58 Cr | -5.37 Cr | 0.28 Cr | 48.8783 Cr |
| 2021-03-31 | 0.88 Cr | 162.08 Cr | 82.93 Cr | 79.1484 Cr | 31.38 Cr | 30.50 Cr | 23.60 Cr | 107.70 Cr | 14.56 Cr | 0.00 Cr | -1.24 Cr | 63.7142 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1.7623 Cr | -46.0409 Cr | 44.1965 Cr | -0.0971 Cr | 0.5546 Cr | 1.2480 Cr | -1.8594 Cr | -9.9670 Cr | 1.0213 Cr | 0.0000 Cr | 0.4060 Cr |
| 2024-03-31 | -9.6806 Cr | 0.1822 Cr | 9.6007 Cr | -10.1196 Cr | 0.1023 Cr | 0.1255 Cr | -0.4390 Cr | -19.5919 Cr | -0.8703 Cr | 0.0000 Cr | 1.6923 Cr |
| 2023-03-31 | -14.4906 Cr | 0.4948 Cr | 11.4140 Cr | -14.9581 Cr | -2.5818 Cr | 0.0232 Cr | -0.4675 Cr | -35.4251 Cr | -4.0322 Cr | 0.0000 Cr | 3.2860 Cr |
| 2022-03-31 | -37.4407 Cr | -24.9086 Cr | 64.0706 Cr | -65.0530 Cr | 1.7211 Cr | 2.6050 Cr | -27.6123 Cr | -23.8977 Cr | -7.2510 Cr | 0.0000 Cr | -3.9193 Cr |
| 2021-03-31 | 4.4587 Cr | -5.1296 Cr | 1.1589 Cr | -1.1551 Cr | 0.4880 Cr | 0.8839 Cr | -5.6138 Cr | -8.9933 Cr | 4.3813 Cr | 0.0000 Cr | -9.8282 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 25.51 Cr | 15.89 Cr | 9.62 Cr | 0.3771 | 2.74 Cr | 9.58 Cr | 3.25 | 10.28 Cr | 0.3757 |
| 2025-03-31 | 23.32 Cr | 19.58 Cr | 3.74 Cr | 0.1602 | 1.15 Cr | -1.46 Cr | -0.48 | 2.16 Cr | -0.0625 |
| 2024-12-31 | 38.45 Cr | 25.06 Cr | 13.38 Cr | 0.3481 | 1.07 Cr | -4.57 Cr | -1.51 | -3.32 Cr | -0.1189 |
| 2024-09-30 | 20.79 Cr | 13.20 Cr | 7.59 Cr | 0.3653 | 1.08 Cr | -3.96 Cr | -1.51 | -3.21 Cr | -0.1906 |
| 2024-06-30 | 17.93 Cr | 12.31 Cr | 5.63 Cr | 0.3138 | -0.12 Cr | -2.41 Cr | -0.94 | -1.85 Cr | -0.1346 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 1.25 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -98.10 Cr |
| 2025-03-31 | 1.25 Cr | 0.00 Cr | 1.25 Cr | 19.99 Cr | 9.20 Cr | 33.88 Cr | 13.97 Cr | 123.69 Cr | 25.59 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 0.81 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -59.21 Cr |
| 2024-09-30 | 0.17 Cr | 2.18 Cr | 2.35 Cr | 23.70 Cr | 9.48 Cr | 37.86 Cr | 14.55 Cr | 91.12 Cr | 31.92 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 0.69 Cr | 0.00 Cr | 0.00 Cr | 0.69 Cr | 0.00 Cr | 0.00 Cr | -65.59 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 9.58 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | -1.46 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | -4.57 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | -3.96 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | -2.41 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2020-02-11 | February 11, 20 | 1199:1000 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,636.20 | ₹3,925,785,949,961.00 | ₹3,109,028.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹5,710.00 | ₹1,515,830,342,520.00 | ₹721,664.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,565.40 | ₹1,206,691,803,000.00 | ₹300,672.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,244.70 | ₹1,036,053,739,575.00 | ₹4,082,857.00 |
| Mankind Pharma Limited | MANKIND | ₹2,440.00 | ₹1,007,130,715,600.00 | ₹218,700.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹994.00 | ₹1,000,192,183,634.00 | ₹560,964.00 |
| Lupin Limited | LUPIN | ₹1,981.30 | ₹904,968,681,500.00 | ₹2,121,417.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,459.50 | ₹652,765,117,500.00 | ₹177,737.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,086.00 | ₹630,750,562,578.00 | ₹1,043,306.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,959.20 | ₹552,887,824,993.00 | ₹524,801.00 |
| Laurus Labs Limited | LAURUSLABS | ₹872.00 | ₹470,727,311,928.00 | ₹2,073,317.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,327.30 | ₹336,741,608,551.00 | ₹253,514.00 |
| Cohance Lifesciences Limited | COHANCE | ₹870.50 | ₹333,024,695,370.00 | ₹176,686.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,398.20 | ₹299,620,613,477.00 | ₹59,582.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,689.70 | ₹264,600,665,038.00 | ₹140,607.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,492.80 | ₹242,557,310,933.00 | ₹804,577.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,222.00 | ₹230,550,000,000.00 | ₹17,995.00 |
| Eris Lifesciences Limited | ERIS | ₹1,624.90 | ₹221,333,403,895.00 | ₹66,608.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹15,386.00 | ₹197,400,672,154.00 | ₹76,750.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹904.30 | ₹177,752,033,033.00 | ₹38,869.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,113.00 | ₹176,467,022,592.00 | ₹116,056.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,058.50 | ₹156,470,076,216.00 | ₹85,382.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹806.55 | ₹144,461,065,649.00 | ₹369,545.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹542.65 | ₹131,670,612,487.00 | ₹2,904,200.00 |
| Procter & Gamble Health Limited | PGHL | ₹6,302.00 | ₹104,609,305,364.00 | ₹8,422.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹778.75 | ₹76,154,669,605.00 | ₹110,903.00 |
| Strides Pharma Science Limited | STAR | ₹819.15 | ₹75,503,278,673.00 | ₹223,057.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹829.10 | ₹75,143,794,598.00 | ₹230,230.00 |
| FDC Limited | FDC | ₹457.30 | ₹74,453,051,413.00 | ₹74,687.00 |
| Innova Captab Limited | INNOVACAP | ₹872.30 | ₹49,917,305,567.00 | ₹25,306.00 |
| Sequent Scientific Limited | SEQUENT | ₹194.90 | ₹48,708,014,270.00 | ₹626,582.00 |
| Suven Life Sciences Limited | SUVEN | ₹207.05 | ₹45,145,326,314.00 | ₹112,355.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹488.05 | ₹44,544,323,500.00 | ₹58,510.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹132.15 | ₹42,885,527,854.00 | ₹193,124.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,264.80 | ₹37,457,561,172.00 | ₹5,746.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹720.15 | ₹36,525,363,466.00 | ₹24,749.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹351.15 | ₹35,214,201,982.00 | ₹25,077.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹482.40 | ₹33,963,733,800.00 | ₹20,154.00 |
| Hikal Limited | HIKAL | ₹255.00 | ₹31,441,691,250.00 | ₹129,465.00 |
| IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹106.99 | ₹31,404,508,295.00 | ₹3,421,704.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹48.81 | ₹26,745,620,048.00 | ₹2,029,317.00 |
| Indoco Remedies Limited | INDOCO | ₹290.15 | ₹26,740,631,661.00 | ₹21,520.00 |
| Alembic Limited | ALEMBICLTD | ₹103.45 | ₹26,564,080,107.00 | ₹495,596.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹605.35 | ₹25,889,578,533.00 | ₹127,415.00 |
Key Executives
President of Procurement
Mr. Rajesh Mahajan MBA
Gender: male
Year Born: 1969
Company Secretary & Compliance Officer
Ms. Krutika Mohan Rane
Gender: female
Year Born: 1993
Whole-Time Director
Mr. Bhushan Singh Rana
Gender: male
Year Born: 1955
Vice President of Sales & Marketing
Nikhil Anand Verma
Gender: Not Specified
Year Born: 1964
President of Corporate Strategy
Mr. Atul Ranchal PGDFMT
Gender: male
Year Born: 1967
Whole Time Director
Dr. Durga Shankar Maity M.Sc.
Gender: Not Specified
Year Born: 1964
Whole Time Director
Mr. Jitendra Pratap Singh
Gender: male
Year Born: 1974
Chief Financial Officer
Mr. Prashant Rathi
Gender: male
Year Born: 1991
FAQs about Brooks Laboratories Limited
Who is the CEO of the company?
The CEO is Prashant Rathi.
What is the current market price of the stock?
The current price is ₹131.76.
What is the 52-week price range?
The range is ₹95.55-198.86.
What is the market capitalization of the company?
The market capitalization is ₹388.13 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is -952.17.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Brooks Laboratories Limited (ISIN: INE650L01011) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹388.13 crores and an average daily volume of 27,014 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.